Adaptimmune Therapeutics plc (NASDAQ:ADAP) Receives $1.83 Consensus Price Target from Analysts

Adaptimmune Therapeutics plc (NASDAQ:ADAP) has been given a consensus rating of “Moderate Buy” by the six research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $1.83.

ADAP has been the subject of several recent analyst reports. Wells Fargo & Company cut their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research report on Friday, March 21st. StockNews.com initiated coverage on shares of Adaptimmune Therapeutics in a research report on Monday. They set a “buy” rating on the stock. Guggenheim lowered their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a research report on Wednesday, March 26th. Scotiabank reduced their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a report on Friday, March 21st. Finally, Jones Trading cut Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, April 11th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Jane Street Group LLC grew its position in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 98,581 shares during the last quarter. Virtu Financial LLC increased its stake in shares of Adaptimmune Therapeutics by 27.5% in the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 21,769 shares during the period. FMR LLC increased its stake in shares of Adaptimmune Therapeutics by 3.0% in the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after buying an additional 50,419 shares during the period. Two Sigma Advisers LP raised its holdings in Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 58,787 shares during the last quarter. Finally, Two Seas Capital LP acquired a new stake in Adaptimmune Therapeutics during the 4th quarter worth approximately $7,992,000. 31.37% of the stock is currently owned by institutional investors.

Adaptimmune Therapeutics Stock Down 0.7 %

NASDAQ ADAP opened at $0.24 on Tuesday. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The company has a market cap of $61.27 million, a price-to-earnings ratio of -1.08 and a beta of 2.84. The company has a 50 day moving average of $0.39 and a 200-day moving average of $0.59. Adaptimmune Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.48.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The company had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. On average, equities research analysts expect that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.